The IMI-funded COMBACTE-MAGNET-consortium, focusing inter alia on the development of AiCuris’ resistance-breaking Gram-negative antibiotic AIC499, announced the start of a retrospective epidemiological study in autumn 2015 to assess the clinical management and outcome of hospitalized patients with complicated urinary tract infection. Results of this study will provide a better understanding of the actual clinical management and the prevalence of MDR Gram-negative pathogens,
22 clinical sites within Europe are already selected. Data collection is planned to be finalized in summer 2016. Academic lead is the University of Barcelona. AiCuris is the responsible EFPIA partner.
Please find here the recent announcement of the COMBACTE-MAGNET-consortium.